Showing 811-820 of 7580 results for "".
ASDS: Dr. Farah on Hair Loss Treatment Options
https://practicaldermatology.com/conferences/asds-2024-annual-meeting/asds-dr-farah-hair-regrowth-options/29152/Ronda Farah, MD, discusses treatment options for hair loss, including platelet-rich plasma and lasers, at the 2024 American Society for Dermatologic Surgery Annual Meeting.Journal Club: New Research in Atopic Dermatitis
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-new-research-in-atopic-dermatitis/26560/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, chats with dermatologist Larry Eichenfield, MD, a member of the Practical Dermatology Editorial Board, about new research in atopic dermatitis (AD), as well as practical considerations and new treatments for the condition.Phio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.Julie Harper, MD, Reacts to New Report on Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/julie-harper-md-reacts-new-report-acne-products-benzoyl-peroxide-bpo/24172/In this video, Julie Harper, MD, a dermatologist with the Dermatology and Skin Care Center of Birmingham, AL, provides her thoughts on the recent Valisure report showing that some common acne products with benzoyl peroxide (BPO) may contain benzene. She says she’s been an “avid prescriber” of acne pDermWireTV: Atopic Dermatitis Guidelines, Derm Devices, and New Research
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-atopic-dermatitis-guidelines-derm-devices-and-new-research/20234/In this episode of DermWire TV, we report on the new atopic dermatitis guidelines, the long-term safety of upadacitinib, and novel energy-based dermatology devices. From the new at-home treatment for molluscum contagiosum to the discovery of genetic factors in early-onset Merkel cell carcinoma, thisFDA Approves Roflumilast for Seborrheic Dermatitis in Young Patients
https://practicaldermatology.com/topics/other-dermatitis/fda-approves-roflumilast-for-seborrheic-dermatitis-in-young-patients/20230/Patrick Burnett, MD, PhD, chief medical officer of Arcutis Biotherapeutics, talks with Practical Dermatology® about the first new treatment for seborrheic dermatitis in more than 20 years, their newly approved ZORYVE (roflumilast)Topical Foam, 0.3% for use in patients aged 9 years or older.Clinical Conversations: The Data for JAK Inhibitors in AD
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad/20105/JAK inhibitors represent a new therapeutic class for the treatment of atopic dermatitis. Find out what the data show about their efficacy and tolerability in a conversation between Brad Glick, DO and Raj Chovatiya, MD. Discover how these drugs can fit into the treatment plan and how these experts diPrescribing Biologics: Don't Be Afraid
https://practicaldermatology.com/conferences/aad-summer-2021/prescribing-biologics-dont-be-afraid/19969/Dermatologists have access to a growing armamentarium of safe and effective systemic therapies, but many physicians and patients are still hesitant to use them. Neal Bhatia, MD discusses the importance of prescribing biologics to patients with moderate to severe psoriasis to offer a safe and efficacDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiPower of the Group: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/power-of-the-group-quality-of-care-in-ad/19880/When researchers undertook a survey of eczema centers worldwide, they uncovered common barriers to care and identified potential solutions. Eric Simpson, MD, MCR provides on overview of the Quality of Care in Atopic Dermatitis initiative, with an emphasis on the value of the group-based analysis of